Jagsonpal Pharma Key Ratios
NSE: JAGSNPHARM | BSE: 507789
₹243.02
As on 03-Sep-2026 15:57IST
Market cap
₹1,600 Cr
Revenue (TTM)
₹294 Cr
P/E Ratio
35.2
P/B Ratio
6.9
Div. Yield
2.3 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 28.08 | 8.76 | 3.87 | 7.54 | 6.91 |
| EBIT | 70.79 | 27.30 | 13.66 | 14.89 | 16.08 |
| Net Profit | 50.52 | 22.18 | 12.52 | 14.57 | 17.08 |
| EPS | 53.10 | 23.46 | 8.90 | 12.71 | 15.93 |
| Book Value | -- | -- | 16.31 | 18.54 | 16.99 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 14.39 | 13.58 | 17.65 | 16.93 | 15.98 |
| Net Margin
| 14.90 | 12.85 | 14.87 | 14.40 | 19.99 |
| Return on equity
| 20.24 | 18.98 | 17.79 | 18.19 | 28.51 |
| Return on Capital
| 24.52 | 23.79 | -- | 22.69 | 33.14 |
| Return on Assets
| 15.57 | 14.45 | 15.29 | 14.18 | 22.02 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.00 | 0.00 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
--
|
22.69
|
33.14
|
17.72
|
24.15
|
|
Peer Median
|
--
|
19.34
|
21.76
|
21.89
|
--
|
ROE
17.79
Higher than Peers by 2.44
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
17.79
|
18.19
|
28.51
|
14.02
|
18.89
|
|
Peer Median
|
15.35
|
17.67
|
17.93
|
16.42
|
--
|
ROA
15.29
Higher than Peers by 4.94
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
15.29
|
14.18
|
22.02
|
10.52
|
14.29
|
|
Peer Median
|
10.35
|
9.88
|
12.81
|
12.32
|
--
|
EBIT Margin
17.65
Lower than Peers by 0.35
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
17.65
|
16.93
|
15.98
|
10.26
|
13.92
|
|
Peer Median
|
18.01
|
18.96
|
18.93
|
21.05
|
--
|
Net Margin
14.87
Higher than Peers by 0.41
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
14.87
|
14.40
|
19.99
|
10.31
|
11.02
|
|
Peer Median
|
14.45
|
13.32
|
14.94
|
15.51
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
--
|
17.25
|
22.53
|
10.75
|
10.86
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
3.87
Lower than Peers by 8.08
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
3.87
|
6.89
|
28.76
|
-11.83
|
8.79
|
|
Peer Median
|
11.95
|
12.97
|
10.90
|
13.44
|
--
|
EBIT Growth
13.66
Lower than Peers by 7.94
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
13.66
|
13.25
|
100.62
|
-35.04
|
40.20
|
|
Peer Median
|
21.60
|
15.05
|
15.01
|
23.50
|
--
|
Net Profit Growth
12.52
Lower than Peers by 10.21
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
12.52
|
-22.18
|
146.45
|
-15.94
|
41.72
|
|
Peer Median
|
22.73
|
11.89
|
14.80
|
30.12
|
--
|
EPS Growth
8.90
Lower than Peers by 11.13
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
8.90
|
-22.84
|
145.32
|
-16.70
|
41.72
|
|
Peer Median
|
20.03
|
12.16
|
14.27
|
29.02
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
--
|
17.30
|
27.98
|
13.46
|
13.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
0.05
|
0.06
|
0.03
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
5.06
Higher than Peers by 2.97
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
5.06
|
3.81
|
6.22
|
9.39
|
4.89
|
|
Peer Median
|
2.08
|
1.93
|
1.90
|
2.23
|
--
|
Quick Ratio
4.54
Higher than Peers by 3.00
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
4.54
|
3.45
|
5.64
|
8.61
|
4.31
|
|
Peer Median
|
1.54
|
1.52
|
1.46
|
1.59
|
--
|
Interest Coverage
60.28
Higher than Peers by 40.91
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
60.28
|
56.95
|
73.92
|
37.69
|
85.28
|
|
Peer Median
|
19.38
|
19.95
|
24.96
|
45.29
|
--
|
Operating Efficiency
Debtors to sales
5.85
Lower than Peers by 15.53
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
5.85
|
5.99
|
4.90
|
5.25
|
8.82
|
|
Peer Median
|
21.38
|
19.87
|
21.77
|
20.10
|
--
|
Asset Turnover
0.99
Higher than Peers by 0.27
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
0.99
|
1.00
|
1.12
|
1.05
|
1.38
|
|
Peer Median
|
0.72
|
0.77
|
0.76
|
0.81
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
--
|
18.20
|
15.63
|
25.88
|
25.87
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
--
|
17.89
|
19.56
|
29.02
|
35.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
--
|
37.27
|
32.80
|
55.17
|
69.43
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
--
|
-1.18
|
2.39
|
-0.27
|
-7.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
35.19
Higher than Peers by 0.12
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
35.19
|
28.65
|
25.90
|
13.17
|
11.37
|
|
Peer Median
|
35.07
|
34.63
|
26.81
|
39.85
|
--
|
Price / Book Value
6.95
Higher than Peers by 1.67
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
6.95
|
4.83
|
6.58
|
4.34
|
5.06
|
|
Peer Median
|
5.28
|
5.52
|
4.65
|
6.11
|
--
|
Dividend Yield
2.27
Higher than Peers by 1.79
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
2.27
|
2.98
|
1.16
|
1.79
|
1.72
|
|
Peer Median
|
0.47
|
0.50
|
0.61
|
0.37
|
--
|
EV/EBITDA
20.44
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
20.44
|
16.10
|
22.02
|
18.30
|
16.17
|
|
Peer Median
|
--
|
29.90
|
27.02
|
34.57
|
--
|
Market Cap
1,600
Lower than Peers by 19,656
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Jagsonpal Pharma
|
1,600
|
1,234
|
1,434
|
740
|
759
|
|
Peer Median
|
21,256
|
18,382
|
20,914
|
25,297
|
--
|